US FDA approves GE HealthCare’s diagnostic drug for the treatment of heart disease

The US Food and Drug Administration has approved a GE HealthCare diagnostic drug for use in the detection of coronary heart disease. Flyrcado, a radioactive diagnostic drug for positron emission tomography (PET) and myocardial perfusion imaging (MPI), will go on sale in some US markets in early 2025, after which it will be expanded.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM